JNCI Journal of the National Cancer Institute最新文献

筛选
英文 中文
Evaluating clinical utility of comprehensive genomic profiling-challenges and opportunities. 评估综合基因组剖析的临床实用性--挑战与机遇。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-08 DOI: 10.1093/jnci/djae237
Lisa M McShane, Lyndsay N Harris
{"title":"Evaluating clinical utility of comprehensive genomic profiling-challenges and opportunities.","authors":"Lisa M McShane, Lyndsay N Harris","doi":"10.1093/jnci/djae237","DOIUrl":"https://doi.org/10.1093/jnci/djae237","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing Capacity for Primary Care Research in Cancer Survivorship: National Cancer Institute Meeting Report. 增强癌症幸存者初级保健研究能力:国家癌症研究所会议报告。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-05 DOI: 10.1093/jnci/djae276
Shawna V Hudson, Michelle A Mollica, Reed Crystal, Erin E Hahn, Denalee M O'Malley, Archana Radhakrishnan, Jennifer Klemp, Emily Tonorezos
{"title":"Enhancing Capacity for Primary Care Research in Cancer Survivorship: National Cancer Institute Meeting Report.","authors":"Shawna V Hudson, Michelle A Mollica, Reed Crystal, Erin E Hahn, Denalee M O'Malley, Archana Radhakrishnan, Jennifer Klemp, Emily Tonorezos","doi":"10.1093/jnci/djae276","DOIUrl":"https://doi.org/10.1093/jnci/djae276","url":null,"abstract":"<p><p>Many components of long-term cancer follow-up and survivorship care are managed in the primary care context. Given the important role that primary care has in survivorship care, it is critical to ensure that teams in these settings are prepared to address long-term needs. Evidence-based strategies to deliver survivorship care in primary care settings in the US remain limited. The National Cancer Institute (NCI) Office of Cancer Survivorship (OCS) conducted a day-long virtual event, Enhancing Capacity for Primary Care Research in Cancer Survivorship: A Workshop for Action, on February 28, 2024, to discuss research needs addressing the intersection between primary care and cancer survivorship. Topics discussed to advance this area of research included: system-level interventions, methods and measurement, and mentorship and research team building, especially for early career researchers. The purpose of this report is to provide a summary of the key findings. Gaps and opportunities include: (1) health systems-level research that investigates primary care practice-level capacity, (2) identification and characterization of the targeted cancer survivor populations for primary care research; (3) leveraging electronic medical records to track relevant patient outcomes throughout survivorship; and (4) development/creation of communities of practice to support and build research capacity. Team science approaches were identified as a core strategy to advance survivorship research. The meeting closed with a reflection and call to action focused on building collaborations that span different research areas, disciplines, and organizations and building a broad network of a primary care practice focused research.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Diverse Aspects of Uterine Serous Cancer: An NCI workshop on the status of and opportunities for advancement of research. 子宫浆液性癌的多样性:美国国家癌症研究所(NCI)关于研究现状和发展机遇的研讨会。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-05 DOI: 10.1093/jnci/djae277
Naveena B Janakiram, Megan A Clarke, Mihoko Kai, Tiffany A Wallace, Sandra Russo, Toby T Hecht, Elise C Kohn, Brandy Heckman-Stoddard
{"title":"The Diverse Aspects of Uterine Serous Cancer: An NCI workshop on the status of and opportunities for advancement of research.","authors":"Naveena B Janakiram, Megan A Clarke, Mihoko Kai, Tiffany A Wallace, Sandra Russo, Toby T Hecht, Elise C Kohn, Brandy Heckman-Stoddard","doi":"10.1093/jnci/djae277","DOIUrl":"https://doi.org/10.1093/jnci/djae277","url":null,"abstract":"<p><p>The marked increase in incidence and mortality in endometrial cancer over the last two decades is driven in part by rising rates of higher grade, more aggressive endometrial cancers with mutations in TP53, uterine serous cancers and their dedifferentiated component, uterine carcinosarcomas (collectively USC). USC rates have been increasing among all racial and ethnic groups, with higher rates of this aggressive uterine cancer in Black women. The National Cancer Institute (NCI) hosted a workshop in June 2023 to examine the diverse aspects of USC across epidemiology, biology, and molecular genetics, and to advance knowledge from basic to preclinical and translational efforts. Key stakeholders came together including basic scientists, clinical investigators, and patient advocates to identify critical research gaps that, when addressed, would facilitate more comprehensive and rapid progress in understanding and ultimately treating USC across all patients. NCI released a supplemental funding opportunity (NOT-CA-24-044) in Spring 2024 to facilitate rapid translation of these recommendations.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression of Concern: Delta-Like Ligand 4-Notch Blockade and Tumor Radiation Response. 表达关切:Delta-Like配体4-Notch阻断与肿瘤放射反应
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-05 DOI: 10.1093/jnci/djae263
{"title":"Expression of Concern: Delta-Like Ligand 4-Notch Blockade and Tumor Radiation Response.","authors":"","doi":"10.1093/jnci/djae263","DOIUrl":"https://doi.org/10.1093/jnci/djae263","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression of Concern: Critical Role for Fas-Associated Death Domain-Like Interleukin-1-Converting Enzyme-Like Inhibitory Protein in Anoikis Resistance and Distant Tumor Formation. 表达关注:Fas 相关死亡结构域类白细胞介素-1-转化酶抑制蛋白在抗药性和远处肿瘤形成中的关键作用。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-04 DOI: 10.1093/jnci/djae264
{"title":"Expression of Concern: Critical Role for Fas-Associated Death Domain-Like Interleukin-1-Converting Enzyme-Like Inhibitory Protein in Anoikis Resistance and Distant Tumor Formation.","authors":"","doi":"10.1093/jnci/djae264","DOIUrl":"https://doi.org/10.1093/jnci/djae264","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prediction of breast cancer risk for adolescents and young adults with Hodgkin lymphoma. 预测青少年和年轻成人霍奇金淋巴瘤患者罹患乳腺癌的风险。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-01 DOI: 10.1093/jnci/djae274
Sander Roberti, Flora E van Leeuwen, Ibrahima Diallo, Florent de Vathaire, Michael Schaapveld, Wendy M Leisenring, Rebecca M Howell, Gregory T Armstrong, Chaya S Moskowitz, Susan A Smith, Berthe M P Aleman, Inge M Krul, Nicola S Russell, Ruth M Pfeiffer, Michael Hauptmann
{"title":"Prediction of breast cancer risk for adolescents and young adults with Hodgkin lymphoma.","authors":"Sander Roberti, Flora E van Leeuwen, Ibrahima Diallo, Florent de Vathaire, Michael Schaapveld, Wendy M Leisenring, Rebecca M Howell, Gregory T Armstrong, Chaya S Moskowitz, Susan A Smith, Berthe M P Aleman, Inge M Krul, Nicola S Russell, Ruth M Pfeiffer, Michael Hauptmann","doi":"10.1093/jnci/djae274","DOIUrl":"10.1093/jnci/djae274","url":null,"abstract":"<p><strong>Background: </strong>While female survivors of Hodgkin lymphoma (HL) have an increased risk of breast cancer (BC), no BC risk prediction model is available. We developed such models incorporating mean radiation dose to the breast or breast quadrant-specific radiation doses.</p><p><strong>Methods: </strong>Relative risks and age-specific incidence for BC and competing events (mortality or other subsequent cancer) were estimated from 1194 Dutch five-year HL survivors, treated at ages 11-40 during 1965-2000. Predictors were doses to ten breast segments or mean breast radiation dose, BC family history, year of and age at HL diagnosis, ages at menopause and first live birth. Models were independently validated using U.S. Childhood Cancer Survivor Study cohort participants.</p><p><strong>Results: </strong>Predicted absolute BC risks 25 years after HL diagnosis ranged from 1.0% for survivors diagnosed at ages 20-24, with <10 Gy mean breast radiation dose and menopausal 5 years after HL diagnosis, to 22.0% for survivors 25-29 years at diagnosis, ≥25 Gy mean breast dose, and no menopause within 5 years. In external validation, the observed/expected BC case ratio was 1.19 (95% confidence interval 0.97 to 1.47) for the breast segment-specific doses model, and 1.29 (1.05 to 1.60) for the mean breast dose model. The areas under the receiver operating characteristic curve were 0.68 (0.63 to 0.74) and 0.68 (0.62 to 0.73), respectively.</p><p><strong>Conclusion: </strong>Breast segment-specific or mean breast radiation dose with personal and clinical characteristics predicted absolute BC risk in HL survivors with moderate discrimination but good calibration, rendering the models useful for clinical decision-making.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142562789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Longitudinal e-Cigarette and Cigarette Use Among US Youth in the PATH Study (2013-2015). 更正:PATH研究(2013-2015年)中美国青少年的电子烟和香烟纵向使用情况》(Longitudinal e-Cigarette and Cigarette Use Among US Youth in the PATH Study (2013-2015))。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-01 DOI: 10.1093/jnci/djae238
{"title":"Correction to: Longitudinal e-Cigarette and Cigarette Use Among US Youth in the PATH Study (2013-2015).","authors":"","doi":"10.1093/jnci/djae238","DOIUrl":"10.1093/jnci/djae238","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1869"},"PeriodicalIF":9.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modeling disparities in colorectal cancer outcomes: colonoscopy follow-up and quality are key. 结肠直肠癌结果差异建模:结肠镜检查随访和质量是关键。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-01 DOI: 10.1093/jnci/djae176
Peter S Liang, Divya Bhatt
{"title":"Modeling disparities in colorectal cancer outcomes: colonoscopy follow-up and quality are key.","authors":"Peter S Liang, Divya Bhatt","doi":"10.1093/jnci/djae176","DOIUrl":"10.1093/jnci/djae176","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1709-1711"},"PeriodicalIF":9.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Older adults with cancer and common comorbidities-challenges and opportunities in improving their cancer treatment outcomes. 患有癌症和常见并发症的老年人--改善癌症治疗效果的挑战与机遇。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-01 DOI: 10.1093/jnci/djae163
Weiwei Chen, Rachel D Altshuler, Phil Daschner, Carolina Salvador Morales, Diane C St Germain, Jennifer Guida, Pataje G S Prasanna, Jeffrey C Buchsbaum
{"title":"Older adults with cancer and common comorbidities-challenges and opportunities in improving their cancer treatment outcomes.","authors":"Weiwei Chen, Rachel D Altshuler, Phil Daschner, Carolina Salvador Morales, Diane C St Germain, Jennifer Guida, Pataje G S Prasanna, Jeffrey C Buchsbaum","doi":"10.1093/jnci/djae163","DOIUrl":"10.1093/jnci/djae163","url":null,"abstract":"<p><p>The older American population is rapidly increasing, and millions of older adults will be cancer survivors with comorbidities. This population faces specific challenges regarding treatment and has unique clinical needs. Recognizing this need, the National Cancer Institute, in collaboration with the National Institute on Aging, hosted a webinar series, entitled Cancer, Aging, and Comorbidities. This commentary provides a reflection of 5 thematic areas covered by the webinar series, which was focused on improving cancer treatment for older adults with cancer and comorbidities: 1) the impact of comorbidities on treatment tolerability and patient outcomes; 2) the impact of comorbidities on cancer clinical trial design; 3) the development of wearable devices in measuring comorbidities in cancer treatment; 4) the effects of nutrition and the microbiome on cancer therapy; and 5) the role of senescence and senotherapy in age-related diseases. Advances have been made in these areas, however, many gaps and challenges exist and are discussed in this commentary. To improve cancer survivorship in older populations with comorbidities, aging and comorbidities must be jointly considered and incorporated across the spectrum of cancer research. This includes more basic research of the mechanisms linking comorbidities and cancer development and treatment response, building critical resources and infrastructure (eg, preclinical models and patient samples), conducting clinical trials focused on the older population, integrating geriatric assessment into cancer treatment, and incorporating novel technologies, such as wearable devices, into clinical trials and cancer care.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1730-1738"},"PeriodicalIF":9.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141599829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework. 利用贝叶斯框架估算卵巢癌筛查的停留时间和敏感性。
IF 9.9 1区 医学
JNCI Journal of the National Cancer Institute Pub Date : 2024-11-01 DOI: 10.1093/jnci/djae145
Sayaka Ishizawa, Jiangong Niu, Martin C Tammemagi, Ehsan Irajizad, Yu Shen, Karen H Lu, Larissa A Meyer, Iakovos Toumazis
{"title":"Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework.","authors":"Sayaka Ishizawa, Jiangong Niu, Martin C Tammemagi, Ehsan Irajizad, Yu Shen, Karen H Lu, Larissa A Meyer, Iakovos Toumazis","doi":"10.1093/jnci/djae145","DOIUrl":"10.1093/jnci/djae145","url":null,"abstract":"<p><strong>Background: </strong>Ovarian cancer is among the leading causes of gynecologic cancer-related death. Past ovarian cancer screening trials using combination of cancer antigen 125 testing and transvaginal ultrasound failed to yield statistically significant mortality reduction. Estimates of ovarian cancer sojourn time-that is, the period from when the cancer is first screen detectable until clinical detection-may inform future screening programs.</p><p><strong>Methods: </strong>We modeled ovarian cancer progression as a continuous time Markov chain and estimated screening modality-specific sojourn time and sensitivity using a Bayesian approach. Model inputs were derived from the screening arms (multimodal and ultrasound) of the UK Collaborative Trial of Ovarian Cancer Screening and the Prostate, Lung, Colorectal and Ovarian cancer screening trials. We assessed the quality of our estimates by using the posterior predictive P value. We derived histology-specific sojourn times by adjusting the overall sojourn time based on the corresponding histology-specific survival from the Surveillance, Epidemiology, and End Results Program.</p><p><strong>Results: </strong>The overall ovarian cancer sojourn time was 2.1 years (posterior predictive P value = .469) in the Prostate, Lung, Colorectal and Ovarian studies, with 65.7% screening sensitivity. The sojourn time was 2.0 years (posterior predictive P value = .532) in the United Kingdom Collaborative Trial of Ovarian Cancer Screening's multimodal screening arm and 2.4 years (posterior predictive P value = .640) in the ultrasound screening arm, with sensitivities of 93.2% and 64.5%, respectively. Stage-specific screening sensitivities in the Prostate, Lung, Colorectal and Ovarian studies were 39.1% and 82.9% for early-stage and advanced-stage disease, respectively. The histology-specific sojourn times ranged from 0.8 to 1.8 years for type II ovarian cancer and 2.9 to 6.6 years for type I ovarian cancer.</p><p><strong>Conclusions: </strong>Annual screening is not effective for all ovarian cancer subtypes. Screening sensitivity for early-stage ovarian cancers is not sufficient for substantial mortality reduction.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1798-1806"},"PeriodicalIF":9.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141748255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信